The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Qiagen met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share dropped significantly.
Gross margins expanded, operating margins shrank, net margins dropped.
Qiagen chalked up revenue of $304.3 million. The 18 analysts polled by S&P Capital IQ wanted to see revenue of $304.7 million on the same basis. GAAP reported sales were 5.3% higher than the prior-year quarter's $288.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.26. The 14 earnings estimates compiled by S&P Capital IQ predicted $0.26 per share. GAAP EPS of $0.12 for Q3 were 20% lower than the prior-year quarter's $0.15 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 65.4%, 50 basis points better than the prior-year quarter. Operating margin was 12.8%, 160 basis points worse than the prior-year quarter. Net margin was 9.6%, 260 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $328.2 million. On the bottom line, the average EPS estimate is $0.31.
Next year's average estimate for revenue is $1.24 billion. The average EPS estimate is $1.04.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 110 members out of 121 rating the stock outperform, and 11 members rating it underperform. Among 36 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 33 give Qiagen a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Qiagen is hold, with an average price target of $17.67.
- Add Qiagen to My Watchlist.